|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Burger M, Catto JW, Dalbagni G, Grossman
HB, Herr H, Karakiewicz P, Kassouf W, Kiemeney LA, La Vecchia C,
Shariat S, et al: Epidemiology and risk factors of urothelial
bladder cancer. Eur Urol. 63:234–241. 2013. View Article : Google Scholar
|
|
3
|
Guillaume L and Guy L: Epidemiology of and
risk factors for bladder cancer and for urothelial tumors. Rev
Prat. 64:1372–1374. 1378–1380. 2014.In French.
|
|
4
|
Almeida M, Canas-Marques R, Lopez-Beltran
A, Rebola J, Lúcio R, Montironi R, Cheng L and Fonseca J: Small
cell carcinoma of the bladder associated with schistosomiasis: A
case report. Anal Quant Cytopathol Histpathol. 36:339–344.
2014.
|
|
5
|
Kumagai T, Takeyama N, Yabuki T, Harada M,
Miki Y, Kanou H, Inoue S, Nakagawa T and Noguchi H: Apheresis of
activated leukocytes with an immobilized polymyxin B filter in
patients with septic shock. Shock. 34:461–466. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Babjuk M, Burger M, Zigeuner R, Shariat
SF, van Rhijn BW, Compérat E, Sylvester RJ, Kaasinen E, Böhle A,
Palou Redorta J, et al: European Association of Urology: EAU
guidelines on non-muscle-invasive urothelial carcinoma of the
bladder: Update 2013. Eur Urol. 64:639–653. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Millán-Rodríguez F, Chéchile-Toniolo G,
Salvador-Bayarri J, Palou J, Algaba F and Vicente-Rodríguez J:
Primary superficial bladder cancer risk groups according to
progression, mortality and recurrence. J Urol. 164:680–684. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Han W, Lou Y, Tang J, Zhang Y, Chen Y, Li
Y, Gu W, Huang J, Gui L, Tang Y, et al: Molecular cloning and
characterization of chemokine-like factor 1 (CKLF1), a novel human
cytokine with unique structure and potential chemotactic activity.
Biochem J. 357:127–135. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Han W, Ding P, Xu M, Wang L, Rui M, Shi S,
Liu Y, Zheng Y, Chen Y, Yang T, et al: Identification of eight
genes encoding chemokine-like factor superfamily members 1–8
(CKLFSF1-8) by in silico cloning and experimental validation.
Genomics. 81:609–617. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Salvi A, Arici B, Portolani N, Giulini SM,
De Petro G and Barlati S: In vitro c-met inhibition by antisense
RNA and plasmid-based RNAi down-modulates migration and invasion of
hepatocellular carcinoma cells. Int J Oncol. 31:451–460.
2007.PubMed/NCBI
|
|
11
|
Polyak K and Weinberg RA: Transitions
between epithelial and mesenchymal states: Acquisition of malignant
and stem cell traits. Nat Rev Cancer. 9:265–273. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hu H, Chen JW, Xu KX, Wang D, Wang Y, Wang
GW, Zhang SY and Wang XF: Expressions of CMTM8 and E-cadherin in
primary and metastatic clear cell renal cell carcinoma. Beijing Da
Xue Xue Bao. 45:537–541. 2013.In Chinese. PubMed/NCBI
|
|
13
|
Choi YK, Woo SM, Cho SG, Moon HE, Yun YJ,
Kim JW, Noh DY, Jang BH, Shin YC, Kim JH, et al: Brain-metastatic
triple-negative breast cancer cells regain growth ability by
altering gene expression patterns. Cancer Genomics Proteomics.
10:265–275. 2013.PubMed/NCBI
|
|
14
|
Zhang W, Mendoza MC, Pei X, Ilter D,
Mahoney SJ, Zhang Y, Ma D, Blenis J and Wang Y: Down-regulation of
CMTM8 induces epithelial-to-mesenchymal transition-like changes via
c-MET/extracellular signal-regulated kinase (ERK) signaling. J Biol
Chem. 287:11850–11858. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Chen SQ, Du Y, Huang YM, Wang X, Gu QL and
Dong ZM: Effects of novel human chemokine-like factor superfamily 8
on proliferation and EGFR expression of HL-60 cells. Zhongguo Shi
Yan Xue Ye Xue Za Zhi. 15:458–461. 2007.In Chinese. PubMed/NCBI
|
|
16
|
Jin C, Ding P, Wang Y and Ma D: Regulation
of EGF receptor signaling by the MARVEL domain-containing protein
CKLFSF8. FEBS Lett. 579:6375–6382. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Jin C, Wang Y, Han W, Zhang Y, He Q, Li D,
Yin C, Tian L, Liu D, Song Q, et al: CMTM8 induces
caspase-dependent and -independent apoptosis through a
mitochondria-mediated pathway. J Cell Physiol. 211:112–120. 2007.
View Article : Google Scholar
|
|
18
|
Black PC and Dinney CP: Growth factors and
receptors as prognostic markers in urothelial carcinoma. Curr Urol
Rep. 9:55–61. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Mellon K, Wright C, Kelly P, Horne CH and
Neal DE: Long-term outcome related to epidermal growth factor
receptor status in bladder cancer. J Urol. 153:919–925. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kassouf W, Black PC, Tuziak T, Bondaruk J,
Lee S, Brown GA, Adam L, Wei C, Baggerly K, Bar-Eli M, et al:
Distinctive expression pattern of ErbB family receptors signifies
an aggressive variant of bladder cancer. J Urol. 179:353–358. 2008.
View Article : Google Scholar
|
|
21
|
Chow NH, Liu HS, Lee EI, Chang CJ, Chan
SH, Cheng HL, Tzai TS and Lin JS: Significance of urinary epidermal
growth factor and its receptor expression in human bladder cancer.
Anticancer Res. 17:1293–1296. 1997.PubMed/NCBI
|
|
22
|
Fu L, Liu N, Han Y, Xie C, Li Q and Wang
E: ADAM10 regulates proliferation, invasion, and chemoresistance of
bladder cancer cells. Tumour Biol. 35:9263–9268. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Prasad SM, Decastro GJ and Steinberg GD:
Medscape: Urothelial carcinoma of the bladder: Definition,
treatment and future efforts. Nat Rev Urol. 8:631–642. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Avgeris M, Mavridis K, Tokas T,
Stravodimos K, Fragoulis EG and Scorilas A: Uncovering the clinical
utility of miR-143, miR-145 and miR-224 for predicting the survival
of bladder cancer patients following treatment. Carcinogenesis.
36:528–537. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wang L, Wu C, Zheng Y, Qiu X, Wang L, Fan
H, Han W, Lv B, Wang Y, Zhu X, et al: Molecular cloning and
characterization of chemokine-like factor super family member 1
(CKLFSF1), a novel human gene with at least 23 alternative splicing
isoforms in testis tissue. Int J Biochem Cell Biol. 36:1492–1501.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Shi S, Rui M, Han W, Wang Y, Qiu X, Ding
P, Zhang P, Zhu X, Zhang Y, Gan Q, et al: CKLFSF2 is highly
expressed in testis and can be secreted into the seminiferous
tubules. Int J Biochem Cell Biol. 37:1633–1640. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zhong J, Wang Y, Qiu X, Mo X, Liu Y, Li T,
Song Q, Ma D and Han W: Characterization and expression profile of
CMTM3/CKLFSF3. J Biochem Mol Biol. 39:537–545. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Li D, Jin C, Yin C, Zhang Y, Pang B, Tian
L, Han W, Ma D and Wang Y: An alternative splice form of CMTM8
induces apoptosis. Int J Biochem Cell Biol. 39:2107–2119. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Neal DE, Marsh C, Bennett MK, Abel PD,
Hall RR, Sainsbury JR and Harris AL: Epidermal-growth-factor
receptors in human bladder cancer: Comparison of invasive and
superficial tumours. Lancet. 1:366–368. 1985. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Both J, Krijgsman O, Bras J, Schaap GR,
Baas F, Ylstra B and Hulsebos TJ: Focal chromosomal copy number
aberrations identify CMTM8 and GPR177 as new candidate driver genes
in osteosarcoma. PLoS One. 9:e1158352014. View Article : Google Scholar
|
|
32
|
Płuciennik E, Nowakowska M, Stępien A,
Wołkowicz M, Stawiński A, Różański W, Lipiński M and Bednarek AK:
Alternating expression levels of WWOX tumor suppressor and
cancer-related genes in patients with bladder cancer. Oncol Lett.
8:2291–2297. 2014.
|
|
33
|
Xie J, Yuan Y, Liu Z, Xiao Y, Zhang X, Qin
C, Sheng Z, Xu T and Wang X: CMTM3 is frequently reduced in clear
cell renal cell carcinoma and exhibits tumor suppressor activities.
Clin Transl Oncol. 16:402–409. 2014. View Article : Google Scholar
|
|
34
|
Sánchez-Pulido L, Martín-Belmonte F,
Valencia A and Alonso MA: MARVEL: A conserved domain involved in
membrane apposition events. Trends Biochem Sci. 27:599–601. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Crew JP, O'Brien T, Bradburn M, Fuggle S,
Bicknell R, Cranston D and Harris AL: Vascular endothelial growth
factor is a predictor of relapse and stage progression in
superficial bladder cancer. Cancer Res. 57:5281–5285.
1997.PubMed/NCBI
|
|
36
|
Trusolino L, Bertotti A and Comoglio PM:
MET signalling: Principles and functions in development, organ
regeneration and cancer. Nat Rev Mol Cell Biol. 11:834–848. 2010.
View Article : Google Scholar : PubMed/NCBI
|
